MLS-573151
(Synonyms: MLS000573151) 目录号 : GC13096
A specific inhibitor of Cdc42
Cas No.:10179-57-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MLS-573151 is a specific and cell permeable inhibitor of Cdc42 [1].
Cdc42 is a small GTPase of the Rho family involved in regulating signaling pathways that control diverse cellular functions such as cell morphology, cell migration, cell cycle progression and endocytosis [2].
In vitro: MLS-573151 was a specific, cell permeable inhibitor of Cdc42 with an IC50 of 2 μM [1]. MLS-573151 showed no effect on other GTPases, including the related Rho family members RhoA, Rac1, and Rac2. MLS-573151 functioned by blocking the binding of GTP to Cdc42 [1]. In marrow-derived mesenchymal stem cells, MLS-573151 showed no effect on cell migration [3].
References:
[1] Surviladze Z, Waller A, Wu Y, et al. Identification of a small GTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay[J]. Journal of biomolecular screening, 2010, 15(1): 10-20.
[2] Qadir M I, Parveen A, Ali M. Cdc42: Role in Cancer Management[J]. Chemical biology & drug design, 2015, 86(4): 432-439.
[3] Wang L, Yang L, Tian L, et al. Cannabinoid Receptor 1 Mediates Homing of Bone Marrow‐Derived Mesenchymal Stem Cells Triggered by Chronic Liver Injury[J]. Journal of cellular physiology, 2017, 232(1): 110-121.
| Cas No. | 10179-57-4 | SDF | |
| 别名 | MLS000573151 | ||
| 化学名 | 4-(4,5-dihydro-3,5-diphenyl-1H-pyrazol-1-yl)-benzenesulfonamide | ||
| Canonical SMILES | NS(C(C=C1)=CC=C1N2C(C3=CC=CC=C3)CC(C4=CC=CC=C4)=N2)(=O)=O | ||
| 分子式 | C21H19N3O2S | 分子量 | 377.5 |
| 溶解度 | ≤20mg/ml in DMSO;30mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.649 mL | 13.245 mL | 26.4901 mL |
| 5 mM | 0.5298 mL | 2.649 mL | 5.298 mL |
| 10 mM | 0.2649 mL | 1.3245 mL | 2.649 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。